Pre-market hot trades in US stocks: Positive clinical trial news fails to boost Fibrobiologics, which falls 7.79% in pre-market trading, raising market concerns

Pre-market Hot Trades in US Stocks Fibrobiologics is down 7.79% in pre-market trading. Based on recent news, On January 5, Fibrobiologics announced that its fibroblast sphere-derived chondrocyte (FSDC) sphere therapy for degenerative disc disease achieved positive results in preclinical trials. This news failed to boost market confidence, leading to a pre-market decline in stock price. Source: Reuters On January 6, Fibrobiologics announced that it will present at the 9th BFC Global Healthcare Business Development and Investment Conference in San Francisco on January 11. Although this news indicates the company's active participation in industry events, it did not prevent the stock price from falling. Source: Public Technologies On January 5, Fibrobiologics released a related announcement via GlobeNewswire, further detailing its preclinical trial results. Despite the positive content of the announcement, market reaction was lukewarm, and the stock price continued to decline. Source: Public Technologies The biotechnology industry has been volatile recently, and investors should exercise caution. Top Gainers in Pre-market US Stocks Aclarion is up 41.57% in pre-market trading. Based on recent news, On January 6, Aclarion announced that it has recruited the first patients at two additional CLARITY trial sites and provided an expected timeline for preliminary data. Preliminary data is expected to be released in the third quarter of 2026, which boosted market confidence and drove the stock price up. On January 6, Aclarion aims to complete the recruitment of 300 patients by mid-2027. The smooth progress of this plan further enhanced investor confidence in the company, resulting in a significant increase in stock price. On January 8, Aclarion confirmed the authenticity of the above news through a GlobeNewswire release, continuing to drive the stock price up. The biotechnology sector has performed strongly recently, and investor sentiment is high. A SPAC III Acquisition is up 33.11% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation. CIMG is up 29.63% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation